Q-omics provides the consensus-scored SEPTIN7P9 profile across patient tissues and cancer cell-line models. SEPTIN7P9 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SEPTIN7P9 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, SEPTIN7P9 RNA expression shows 17,752 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where SEPTIN7P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPTIN7P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPTIN7P9 survival associations across molecular data types. SEPTIN7P9 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPTIN7P9 RNA expression–survival associations across cancer types. High SEPTIN7P9 expression shows unfavorable associations in ACC, KIRC and THCA, but favorable associations in HNSC, STAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SEPTIN7P9 RNA expression.
This table summarizes SEPTIN7P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SEPTIN7P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPTIN7P9 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in BLCA, LIHC and STAD. The KICH box plot shows higher SEPTIN7P9 RNA expression in normal versus tumor tissue (log2 FC = −0.550, t-test p < 0.001).
This table shows molecular features associated with SEPTIN7P9 in patient tissues and cancer cell lines. In patient samples, SEPTIN7P9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
